AltruBio
8 known investors
Find your way into AltruBio
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.
Investors · 8
aMoonRa'anana
Delos CapitalCambridge
RA CapitalBoston
Biotechnology Value Fundreported · 2 sourcesSan Francisco
Soleus Capitalreported · 2 sourcesGreenwich
Also in the syndicate · 3
aMoon FundleadBlackstone Multi-Asset InvestingCormorant Asset Management
Funding
SEC filings, press & company announcements$225M disclosed across 1 of 2 rounds · 2021–2024
- $225MSeries BMay 2024 · 5 sources
aMoon Fund (lead), BVF Partners (lead), Blackstone Multi-Asset Investing, Cormorant Asset Management, Delos Capital, RA Capital Management, Soleus Capital
Source ↗ - Undisclosed amountSeries AApr 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does AltruBio do?
- AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.
- Who are AltruBio's investors?
- AltruBio's investors include aMoon, Delos Capital, RA Capital, Biotechnology Value Fund, Soleus Capital.
- How much funding has AltruBio raised?
- AltruBio has disclosed $225M raised across 1 of its 2 known rounds.